Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06329570 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
A Phase 1 study, sponsored by NaviFUS Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06329570 is a Phase 1 study that is actively recruiting participants, run by NaviFUS Corporation. The registered enrollment target is 10 participants.
The verdict
NCT06329570, a Phase 1 study, is actively recruiting participants, sponsored by NaviFUS Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.
Interventions
- DRUG Bevacizumab
- DRUG Lumason
- DEVICE NaviFUS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06329570
The ClinicalTrials.gov registry entry for NCT06329570 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NaviFUS Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06329570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06329570 about?
NCT06329570 is a clinical study titled "Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)". This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previou...
What is the current status of trial NCT06329570?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-10-22. Estimated completion is 2028-03-31.
What interventions are being tested in trial NCT06329570?
The interventions under investigation include: Bevacizumab (DRUG), Lumason (DRUG), NaviFUS System (DEVICE).
Who is sponsoring clinical trial NCT06329570?
This trial is sponsored by NaviFUS Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.